Pelthos Therapeutics Inc. has 11 Schedule 13D or 13G filings on record since 2025-07-03. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | 49.9% | 5,189,177 | SCHEDULE 13D/A, 2025-11-10 | 2025-11-06 |
| 3i, LP | 9.9% | 337,026 | SCHEDULE 13G/A, 2026-05-07 | 2026-03-31 |
| Murchinson Ltd. | 9.1% | 280,000 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Ezra Friedberg | 8.3% | 250,121 | SCHEDULE 13D/A, 2025-07-03 | 2025-07-01 |
| Ikarian Capital, LLC | 7.7% | 256,598 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| AME Equities LLC | 0% | 0 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
Purpose of Transaction (Item 4)
Ligand Pharmaceuticals Incorporated
Item 4 of the Schedule 13D is hereby supplemented as follows: Convertible Note Financing On November 6, 2025, Ligand entered into the Convertible Note Purchase Agreement with the Issuer and the other investors party thereto, pursuant to which the Issuer issued and sold to Ligand $9.0 million aggregate principal amount of Convertible Notes. The Convertible Notes Issuance closed on November 6, 2025. The Convertible Notes mature 24 months from the date of issuance. The Convertible Notes bear interest at a rate of 8.5% per annum, payable quarterly in arrears, which may, at the Issuer's option, be paid in cash or capitalized and added to principal. The Convertible Notes rank senior to current and future indebtedness of the Issuer and its subsidiaries, other than certain senior indebtedness permitted under the terms of the Convertible Note ("Permitted Senior Indebtedness"). The Convertible Notes are convertible by the holders thereof in whole or in part at any time after issuance into shares of Common Stock based on an initial conversion price equal to $34.442 per share (the "Conversion Price"), which cannot be reduced below $34.442 per share without obtaining the approval of the shareholders of the Issuer (the "Shareholder Approval"), and is subject to customary adjustments for stock splits, stock dividends, recapitalization and other similar transactions. On the later of December 1, 2025 and the date the Issuer obtains the Shareholder Approval, if any, if the Conversion …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-10; the filing has the rest
Ezra Friedberg
"Item 4: Purpose of Transaction" is not being amended by this Amendment No. 1.Item 4 of the SCHEDULE 13D/A filed 2025-07-03
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | Ligand Pharmaceuticals Incorporated | 49.9% | SCHEDULE 13D |
| 2025-07-03 | Ezra Friedberg | 8.3% | SCHEDULE 13D/A |
| 2025-07-08 | 3i, LP | 9.9% | SCHEDULE 13G |
| 2025-08-13 | AME Equities LLC | 0% | SCHEDULE 13G/A |
| 2025-11-10 | Ligand Pharmaceuticals Incorporated | 49.9% | SCHEDULE 13D/A |
| 2025-11-14 | Ikarian Capital, LLC | 6.1% | SCHEDULE 13G/A |
| 2025-11-14 | Murchinson Ltd. | 9.1% | SCHEDULE 13G |
| 2026-02-05 | 3i, LP | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Ikarian Capital, LLC | 8.4% | SCHEDULE 13G/A |
| 2026-05-07 | 3i, LP | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Ikarian Capital, LLC | 7.7% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Pelthos Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.